Ilumya

Active Ingredient(s): Tildrakizumab-asmn
FDA Approved: * March 20, 2018
Pharm Company: * MERCK SHARP DOHME
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ilumya Overview

Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1] It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.[2][3][4] Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immun...

Read more Ilumya Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tildrakizumab

Recent Ilumya Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tildrakizumab-asmn
  • Injection: 100mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ilumya: (1 result)

Sorted by National Drug Code
  • 47335-177 Ilumya 100 mg/ml Subcutaneous Injection, Solution by Sun Pharma Global Fze

Other drugs which contain Tildrakizumab-asmn or a similar ingredient: (1 result)